Last Updated on August 13, 2024 by The Health Master
CDSCO approval
Sanofi India has made a significant stride in infant healthcare with the recent CDSCO approval of its RSV prevention drug, Beyfortus, by the Central Drugs Standard Control Organisation (CDSCO).
This groundbreaking medication is designed to protect newborns, infants, and young children from the potentially severe consequences of Respiratory Syncytial Virus (RSV) infection.
RSV is a highly contagious virus that can cause severe lower respiratory tract disease (LRTD) in infants.
The infection can lead to hospitalization and, in some cases, even be fatal.
Until now, there has been no effective way to prevent RSV, making the CDSCO approval of Beyfortus a game-changer for parents and healthcare providers alike.
How Beyfortus Works
Beyfortus is administered as a single injection and provides protection against RSV for the entire RSV season.
It is specifically approved for:
- Newborns and infants born during or entering their first RSV season
- Children up to 24 months of age who remain vulnerable to severe RSV disease
A Landmark Achievement for Sanofi India
The CDSCO approval of Beyfortus marks a pivotal moment for Sanofi India.
Preeti Futnani, General Manager of Sanofi Vaccines (India), emphasized the unmet medical need for RSV prevention in India and highlighted the significance of this CDSCO approval.
A Collaborative Effort
It’s important to note that Beyfortus is a product of collaboration between Sanofi and AstraZeneca.
In 2017, the two pharmaceutical giants joined forces to develop and commercialize this innovative drug.
While AstraZeneca led the development and manufacturing processes, Sanofi took the reins on commercialization and will be responsible for bringing Beyfortus to patients in India and other markets.
The availability of Beyfortus represents a major step forward in safeguarding the health of infants and young children.
With this new preventive measure, parents can have greater peace of mind knowing their little ones are protected from the potentially devastating effects of RSV.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
India seeks new Head for Drug Regulators CDSCO
DCGI announces Stringent Measures and Digital Transformation Plans
Latest Circulars, Notices & Guidelines: CDSCO, DCGI
CDSCO Panel approval granted for this Anti Cancer Drug
DCGI approval granted for this new Antibiotic Drug Combination
CDSCO: Updated version of guidance document for Biologicals
Human Error: The Silent Killer of the Indian Pharma Industry
Drug Recall in India: A Growing Concern
USFDA India appoints Greg Smith as New Director
RBI: Indian Pharma Industry faces Quality Control Overhaul
How the NPPA Regulates Medicine Prices in India
India seeks new Head for Drug Regulators CDSCO
Jyoti Sardesai a veteran Administrator retires after Four Decades of Service
India to ease Rules for import of EU Approved Medical Devices
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
